Tamila L. Kindwall-Keller Columnista Experta de SIIC Medical Oncology Fellow, Division of Hematology/Oncology. Arthur G. James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, EE.UU.

ELINAFIDA, ESTADO ACTUAL DE UNA NAFTALIMIDA ACTIVA Columnista Experta de SIIC Tamila L. Kindwall-Keller en colaboración con Miguel A. Villalona-Calero, Medical Oncologist, Associate Professor of Medicine. Division of Hematology/Oncology. Arthur G. James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University Fecha de aprobación: Primera edición en siicsalud: 8 de Abril, 2003 Sección Artículos originales, subsección Expertos del Mundo, página http://www.siicsalud.com/des/des031/03407001.htm   Especialidad principal: Farmacología. Especialidades relacionadas:  Oncología,  Medicina Interna. Hypermethylation induced decrease in Sp1/Sp3 binding is associated with reduced p21Cip1 expression in response to depsipeptide treatment Molecular and Cellular Biology. (Accepted Pending Revisions) , 0 Lung specific expression of mutant p53 (273H) results in high frequency of lung adenocarcinoma in transgenic mice Oncogene (In Press) , 0 Mitomycin C as a Modulator of Irinotecan Anticancer Activity Oncology 16(8, supp 7):21-25, 2002 A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies Clinical Cancer Research 8:2142-2148, 2002 Pharmaco-biologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies Journal of Clinical Oncology 20:2616-2623, 2002 A pilot trial of G3139, a bcl-2 antisense oligonucleotide, with paclitaxel in patients with chemorefractory small cell lung cancer Annals of Oncology 13:539-45, 2002 Detection of transgene and host endogenous homologous gene expression and silencing using RT-PCR-Heteroduplex technique in transgenic animal models Biotechniques 33:58-66, 2002 A Phase I And Pharmacokinetic Study of ET-743, a Novel DNA Minor Groove Binder of Marine Origin Administered as a 1-hour infusion daily x 5 Days Clinical Cancer Research 8:75-85, 2002 A Phase I And Pharmacokinetic Study of ET-743, a Novel DNA Minor Groove Binder of Marine Origin Administered as a 1-hour infusion daily x 5 Days , 0 A Phase I And Pharmacokinetic Study of ET-743, a Novel DNA Minor Groove Binder of Marine Origin Administered as a 1-hour infusion daily x 5 Days Annals of Oncology 12(5):605-614, 2001 Dr.  Tamila L. Kindwall-Keller Dirección profesional: Arthur G. James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University A437A, Starling-Loving Hall, 320 West Tenth Ave., Columbus, Ohio 43210

Bienvenidos a siicsalud
Acerca de SIIC] [Estructura de SIIC]

Sociedad Iberoamericana de Información Científica (SIIC)
Av. Belgrano 430, (C1092AAR), Buenos Aires, Argentina
atencionallector@siicsalud.com; Tel: +54 11 4342-4901; Fax: +54 11 4331-3305.
Casilla de Correo 2568, (C1000WAZ)  Correo Central, Buenos Aires.
Copyright siicsalud© 1997- 2006, Sociedad Iberoamericana de Información Científica (SIIC)